Open, Randomized, 2-period, 2-sequence, Cross-over Relative Bioavailability Study to Investigate the Pharmacokinetics and to Assess the Bioequivalence of a Rivastigmine Test Patch Formulation 9.5 mg/24 h (Twice-weekly Patch) (Luye Pharma AG, Germany) Compared to the Reference Patch Exelon® 9.5 mg/24 h (Once-daily Patch) (LTS Lohmann Therapie-Systeme AG, Germany) Applied for 11 Days
Latest Information Update: 07 Feb 2024
At a glance
- Drugs Rivastigmine (Primary)
- Indications Alzheimer's disease
- Focus Pharmacokinetics; Therapeutic Use
- Sponsors Luye Pharma Group
- 01 Feb 2024 Status changed from active, no longer recruiting to completed.
- 09 May 2019 Status changed to completed, according to a Luye Pharma media release.
- 09 May 2019 Results published in the Luye Pharma Group Media Release.